1. Home
  2. IKNA vs KF Comparison

IKNA vs KF Comparison

Compare IKNA & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • KF
  • Stock Information
  • Founded
  • IKNA 2016
  • KF 1984
  • Country
  • IKNA United States
  • KF United States
  • Employees
  • IKNA N/A
  • KF N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • KF Investment Managers
  • Sector
  • IKNA Health Care
  • KF Finance
  • Exchange
  • IKNA Nasdaq
  • KF Nasdaq
  • Market Cap
  • IKNA 81.6M
  • KF 94.9M
  • IPO Year
  • IKNA 2021
  • KF N/A
  • Fundamental
  • Price
  • IKNA $1.45
  • KF $19.70
  • Analyst Decision
  • IKNA Buy
  • KF
  • Analyst Count
  • IKNA 2
  • KF 0
  • Target Price
  • IKNA $3.00
  • KF N/A
  • AVG Volume (30 Days)
  • IKNA 134.5K
  • KF 18.4K
  • Earning Date
  • IKNA 03-11-2025
  • KF 01-01-0001
  • Dividend Yield
  • IKNA N/A
  • KF N/A
  • EPS Growth
  • IKNA N/A
  • KF N/A
  • EPS
  • IKNA N/A
  • KF N/A
  • Revenue
  • IKNA $659,000.00
  • KF N/A
  • Revenue This Year
  • IKNA N/A
  • KF N/A
  • Revenue Next Year
  • IKNA N/A
  • KF N/A
  • P/E Ratio
  • IKNA N/A
  • KF N/A
  • Revenue Growth
  • IKNA N/A
  • KF N/A
  • 52 Week Low
  • IKNA $1.22
  • KF $18.30
  • 52 Week High
  • IKNA $1.94
  • KF $25.56
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 36.12
  • KF 43.96
  • Support Level
  • IKNA $1.45
  • KF $19.71
  • Resistance Level
  • IKNA $1.53
  • KF $20.17
  • Average True Range (ATR)
  • IKNA 0.06
  • KF 0.25
  • MACD
  • IKNA -0.00
  • KF -0.01
  • Stochastic Oscillator
  • IKNA 23.53
  • KF 24.48

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.

Share on Social Networks: